Moreover, as MDM2 inhibitors are already available for clinical use, we propose to test them in a clinical trial to assess whether or not their administration would improve the results of TNF-based ILP in patients with in-transit melanoma metastasis. The gene discussed is MDM2; the disease is melanoma.